AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16846551 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 6743
Study 15670201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily (n = 12)
Number of subjects: 37
Study 15670201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg twice weekly (n = 11)
Number of subjects: 37
Study 15670201 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily (n = 14)
Number of subjects: 37
Study 11930855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner care
Number of subjects: 79
Study 9480230 — intervention group
Group type: EXPERIMENTAL
Intervention: Camit-Diacomp system
Number of subjects: 2
Study 9480230 — intervention group
Group type: COMPARATOR
Intervention: Standard insulin treatment without Camit-Diacomp system
Number of subjects: 2
Study 8173753 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PGE2
Number of subjects: 8
Study 8173753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3294920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaspirone, treated for 28 days
Number of subjects: 14
Study 31893985 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial enlargement
Number of subjects: 3983
Study 31893985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral plaque
Number of subjects: 3983
Study 31893985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both left atrial enlargement and ipsilateral plaque
Number of subjects: 3983
Study 31893985 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between left atrial dimension and ipsilateral plaque
Number of subjects: 3983
Study 31893985 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary markers of atrial cardiopathy
Number of subjects: 3983
Study 29618162 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (175 IU/kg once daily)
Number of subjects: 864
Study 29618162 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 864
Study 26805417 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐t‐butylcyclohexanol
Number of subjects: 0
Study 26805417 — intervention group
Group type: EXPERIMENTAL
Intervention: Licochalcone A
Number of subjects: 0
Study 26805417 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation containing 4‐t‐butylcyclohexanol
Number of subjects: 0
Study 26805417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream base containing 4‐t‐butylcyclohexanol and licochalcone A
Number of subjects: 0
Study 24726785 — intervention group
Group type: EXPERIMENTAL
Intervention: ESMI group
Number of subjects: 196
Study 23128469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU once daily for 12 weeks)
Number of subjects: 36
Study 20795425 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL fish oil daily (550 mg eicosapentaenoic acid; 205 mg decosahexaenoic acid)
Number of subjects: 36
Study 20795425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20795425 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL fish oil daily
Number of subjects: 36
Study 18834296 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintegration training program
Number of subjects: 128
Study 18834296 — intervention group
Group type: COMPARATOR
Intervention: Booster sessions
Number of subjects: 128
Study 17058827 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine CHD plus Salvia miltiorrhiza (SM)
Number of subjects: 36
Study 17058827 — intervention group
Group type: COMPARATOR
Intervention: Routine CHD
Number of subjects: 36
Study 17058827 — intervention group
Group type: COMPARATOR
Intervention: Normal control (healthy adults)
Number of subjects: 36
Study 12826985 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (150 mg) once daily
Number of subjects: 25
Study 12826985 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion (300 mg)
Number of subjects: 25
Study 12826985 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate SR (20 mg daily)
Number of subjects: 25
Study 12826985 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 11256129 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia using Propofol/Sufentanil (TIVA)
Number of subjects: 0
Study 11256129 — intervention group
Group type: COMPARATOR
Intervention: Balanced inhalational anaesthesia using Trapanal/Sevoflurane (BIA)
Number of subjects: 0
Study 9006528 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐mg/kg cefdinir, twice daily, for 5 days
Number of subjects: 440
Study 9006528 — intervention group
Group type: COMPARATOR
Intervention: 10‐mg/kg penicillin V potassium, 4 times daily, for 10 days
Number of subjects: 440
Study 8314358 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (5 mg o.d.)
Number of subjects: 16
Study 8314358 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (100 mg o.d.)
Number of subjects: 16
Study 8314358 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 3475771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 100
Study 3475771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31815684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 29
Study 31815684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Compression (IC)
Number of subjects: 29
Study 31815684 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 30539289 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100F/HMPnano
Number of subjects: 12
Study 30539289 — intervention group
Group type: COMPARATOR
Intervention: 1100F
Number of subjects: 12
Study 27440250 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploring Feelings CBT intervention (n=18)
Number of subjects: 35
Study 27440250 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=17)
Number of subjects: 35
Study 25336623 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-PCR group (serum GM and PCR assays results provided)
Number of subjects: 219
Study 25336623 — intervention group
Group type: COMPARATOR
Intervention: GM group (only serum GM results informed)
Number of subjects: 219
Study 25336623 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-PCR group
Number of subjects: 219
Study 25336623 — intervention group
Group type: COMPARATOR
Intervention: GM group
Number of subjects: 219
Study 23204220 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 2000 IU/day
Number of subjects: 267
Study 23204220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 21543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up visits (more than recommended)
Number of subjects: 579
Study 21543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic detection at routine visit
Number of subjects: 579
Study 21543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic detection at routine visit
Number of subjects: 579
Study 21543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis after an interval visit
Number of subjects: 579
Study 21543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection method comparison
Number of subjects: 579
Study 21543930 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from primary treatment to recurrence
Number of subjects: 579
Study 19405756 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial sunscreens characterized by USPF
Number of subjects: 0
Study 19405756 — intervention group
Group type: COMPARATOR
Intervention: USPF obtained for human skin
Number of subjects: 0
Study 19405756 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine skin
Number of subjects: 0
Study 17715049 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target controlled infusion (TCI)
Number of subjects: 60
Study 17715049 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane inhalational anesthesia
Number of subjects: 60
Study 15549974 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol‐Lipuro
Number of subjects: 200
Study 15549974 — intervention group
Group type: COMPARATOR
Intervention: Diprivan mixed with lidocaine 10 mg
Number of subjects: 200
Study 11911312 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU intravenous injection at 1000 mg/m2 body surface area/24 hours for 72 hours + oral HCFU 300 mg daily for 52 weeks (Group B)
Number of subjects: 314
Study 11911312 — intervention group
Group type: COMPARATOR
Intervention: 5-FU intravenous injection at 333 mg/m2 body surface area/24 hours for 72 hours + oral HCFU 300 mg daily for 52 weeks (Group A)
Number of subjects: 314
Study 11911312 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 314
Study 9855228 — intervention group
Group type: EXPERIMENTAL
Intervention: Boneloc bone cement
Number of subjects: 19
Study 9855228 — intervention group
Group type: COMPARATOR
Intervention: Palacos bone cement
Number of subjects: 19
Study 7889236 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 2493100 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin paste
Number of subjects: 26
Study 2493100 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment base
Number of subjects: 26
Study 31974753 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser moxibustion
Number of subjects: 392
Study 31974753 — intervention group
Group type: COMPARATOR
Intervention: Sham laser moxibustion
Number of subjects: 392
Study 31243778 — intervention group
Group type: EXPERIMENTAL
Intervention: HALTHCC risk score (preoperatively calculated continuous risk score)
Number of subjects: 4089
Study 31243778 — intervention group
Group type: EXPERIMENTAL
Intervention: HALTHCC score before recalibration
Number of subjects: 4089
Study 31243778 — intervention group
Group type: EXPERIMENTAL
Intervention: HALTHCC score after recalibration
Number of subjects: 4089
Study 28853303 — intervention group
Group type: EXPERIMENTAL
Intervention: DASHNa‐CC intervention (Dietary Approach to Stop Hypertension With Sodium Reduction for Chinese Canadian)
Number of subjects: 60
Study 28853303 — intervention group
Group type: EXPERIMENTAL
Intervention: DASHNa‐CC intervention
Number of subjects: 60
Study 26074293 — intervention group
Group type: EXPERIMENTAL
Intervention: Desarda repair
Number of subjects: 168
Study 26074293 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 168
Study 23562009 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP 150 mg
Number of subjects: 621
Study 23562009 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP 300 mg
Number of subjects: 621
Study 23562009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 21796092 — intervention group
Group type: EXPERIMENTAL
Intervention: PEVAR with adjunctive 'pre-close' techniques using ProGlide or Prostar XL devices
Number of subjects: 38
Study 19921354 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol infusion (0.125 mg kg(‐1) min(‐1) for 1 min, then 0.04 mg kg(‐1) min(‐1) until extubation)
Number of subjects: 63
Study 19921354 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol infusion
Number of subjects: 63
Study 19921354 — intervention group
Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 63
Study 16963585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic antidepressant treatment
Number of subjects: 59
Study 16963585 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy conditions
Number of subjects: 59
Study 15673949 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/day for 3 weeks
Number of subjects: 20
Study 15673949 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 15 mg/day for 3 weeks
Number of subjects: 20
Study 11732147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 0
Study 11732147 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 0
Study 9129961 — intervention group
Group type: EXPERIMENTAL
Intervention: U.S. blacks
Number of subjects: 0
Study 9129961 — intervention group
Group type: COMPARATOR
Intervention: Nigerians
Number of subjects: 0
Study 8722923 — intervention group
Group type: EXPERIMENTAL
Intervention: Derived 12-lead electrocardiogram
Number of subjects: 250
Study 8722923 — intervention group
Group type: COMPARATOR
Intervention: Routine monitoring of leads V1 and II
Number of subjects: 250
Study 2265331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 145
Study 2265331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 145
Study 2265331 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Avafortan
Number of subjects: 145
Study 2265331 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of prostaglandin synthetase inhibitors
Number of subjects: 145
Study 6445225 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and 5-Fluorouracil
Number of subjects: 0
Study 6445225 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate and streptozotocin
Number of subjects: 0
Study 6445225 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednimustine and imidazole carboxamide (DTIC)
Number of subjects: 0
Study 6445225 — intervention group
Group type: EXPERIMENTAL
Intervention: DES combined with cyclophosphamide
Number of subjects: 0
Study 6445225 — intervention group
Group type: COMPARATOR
Intervention: Methyl-CCNU and hydroxyurea
Number of subjects: 0
Study 6445225 — intervention group
Group type: COMPARATOR
Intervention: Estramustine phosphate and vincristine
Number of subjects: 0
Study 6445225 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and estramustine phosphate
Number of subjects: 0
Study 31120555 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut allergy (PNA) diagnosis
Number of subjects: 511
Study 31120555 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate factors associated with PNA
Number of subjects: 511
Study 31120555 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 511
Study 31120555 — intervention group
Group type: EXPERIMENTAL
Intervention: Models using stricter or less strict PNA criteria
Number of subjects: 511
Study 28288302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle warm-up (IMW) comprising 2 × 30 inspiratory efforts against a pressure-threshold load of 40% maximal inspiratory pressure (PImax)
Number of subjects: 9
Study 28288302 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min unloaded running (AWU) at lactate turnpoint (10.33 ± 1.58 km·h‐1)
Number of subjects: 9
Study 28288302 — intervention group
Group type: COMPARATOR
Intervention: Placebo inspiratory muscle warm-up (PLA) comprising 5-min breathing using a sham device
Number of subjects: 9
Study 28288302 — intervention group
Group type: EXPERIMENTAL
Intervention: AWU+IMW
Number of subjects: 9
Study 28288302 — intervention group
Group type: EXPERIMENTAL
Intervention: AWU+PLA
Number of subjects: 9
Study 26341820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 250
Study 26341820 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief support (monthly weigh-ins and meeting)
Number of subjects: 250
Study 26341820 — intervention group
Group type: EXPERIMENTAL
Intervention: App (use of MyFitnessPal with limited support)
Number of subjects: 250
Study 26341820 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing (with brief monthly feedback)
Number of subjects: 250
Study 26341820 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger training (four-week programme which trains individuals to only eat when physically hungry)
Number of subjects: 250
Study 24947922 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal material that was strictly healthy
Number of subjects: 250
Study 24947922 — intervention group
Group type: EXPERIMENTAL
Intervention: Solely professional material
Number of subjects: 250
Study 24947922 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal material that included unhealthy behavior
Number of subjects: 250
Study 24947922 — intervention group
Group type: EXPERIMENTAL
Intervention: Female profiles
Number of subjects: 250
Study 22668675 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaningful task-specific training (MTST)
Number of subjects: 103
Study 22668675 — intervention group
Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 103
Study 20430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 1400
Study 20430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1400
Study 20430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1400
Study 20430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-controlling medications
Number of subjects: 1400
Study 20430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1400
Study 20430112 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1400
Study 17494791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 24
Study 17494791 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 24
Study 15714841 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent management training
Number of subjects: 33
Study 15714841 — intervention group
Group type: COMPARATOR
Intervention: Control group (medication with methylphenidate plus consultation)
Number of subjects: 33
Study 12046876 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided customized ablation
Number of subjects: 11
Study 12046876 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 11
Study 10405869 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a year deworming with single dose mebendazole
Number of subjects: 3028
Study 10405869 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times a year deworming
Number of subjects: 3028
Study 10405869 — intervention group
Group type: COMPARATOR
Intervention: Control group (no deworming)
Number of subjects: 3028
Study 8839508 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched feeding
Number of subjects: 28
Study 8839508 — intervention group
Group type: COMPARATOR
Intervention: Standard peptide-based feeding (control)
Number of subjects: 28
Study 1636398 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear thinning time
Number of subjects: 34
Study 1636398 — intervention group
Group type: EXPERIMENTAL
Intervention: Schirmer tear test
Number of subjects: 34
Study 1636398 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of dry eyes
Number of subjects: 34
Study 6609807 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation (ES)
Number of subjects: 0
Study 6609807 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study 31595044 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu‐DOTA‐PSMA‐617 (177Lu‐PSMA‐617)
Number of subjects: 0
Study 31806610 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing the nail plate after nail bed repair
Number of subjects: 416
Study 31806610 — intervention group
Group type: COMPARATOR
Intervention: Discarding the nail plate after nail bed repair
Number of subjects: 416
Study 28595839 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery (group I)
Number of subjects: 50
Study 28595839 — intervention group
Group type: COMPARATOR
Intervention: Conventional osteotomy (group II)
Number of subjects: 50
Study 26364905 — intervention group
Group type: EXPERIMENTAL
Intervention: Target oxygen saturation of ≥ 90% (modified care)
Number of subjects: 615
Study 26364905 — intervention group
Group type: COMPARATOR
Intervention: Target oxygen saturation of ≥ 94% (standard care)
Number of subjects: 615
Study 23648788 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF-1 (nonhydrolyzed protein, locust bean gum)
Number of subjects: 115
Study 23648788 — intervention group
Group type: EXPERIMENTAL
Intervention: ARF-2 (specific whey hydrolysate, locust bean gum, specially treated starch)
Number of subjects: 115
Study 23648788 — intervention group
Group type: COMPARATOR
Intervention: ARF-1
Number of subjects: 115
Study 21858008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with Normosol-R (n=20)
Number of subjects: 48
Study 21858008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with saline (n=14)
Number of subjects: 48
Study 21858008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicovaginal lavage (CVL) with water (n=14)
Number of subjects: 48
Study 21858008 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical swabs
Number of subjects: 48
Study 21858008 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical and vaginal flocked swabs
Number of subjects: 48
Study 21858008 — intervention group
Group type: COMPARATOR
Intervention: Dacron swabs
Number of subjects: 48
Study 19700413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and podophyllotoxin 0.15% cream
Number of subjects: 140
Study 19700413 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy alone
Number of subjects: 140
Study 17933157 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of risperidone
Number of subjects: 126
Study 17933157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 15292666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract LI160 (300 mg twice a day for 2 weeks)
Number of subjects: 19
Study 15292666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11148433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 60
Study 11148433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8262685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal therapeutic system (TTS)
Number of subjects: 160
Study 8262685 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal therapeutic system (TTS)
Number of subjects: 160
Study 3898725 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-80 mg, most frequently 40 mg)
Number of subjects: 60
Study 3898725 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (60-120 mg, most frequently 90 mg)
Number of subjects: 60